Featured

Status

Health Topics

Any Category
Diseases
Cardiovascular Diseases
Vascular Diseases
Clear Filters

Search Clinical Trials

10 Results
Recruiting
Fetal Endotracheal Occlusion (FETO) in the Resolution of Pulmonary Hypertension in Fetuses With Severe CDH
Enrollment Women carrying a fetus with severe CDH and a normal karyotype will undergo routine clinical evaluation. The fetus will be 28+0/7 to 31+6/7 weeks of gestational age and have …
Baylor Role: Collaborator
Completed
Chronic Hypertension and Pregnancy (CHAP) Project
During pregnancy, chronic hypertension (CHTN) is the most common major medical disorder encountered, occurring in 2-6%. The substantial negative effect of CHTN on pregnancy includes a consistent 3- to 5-fold …
Baylor Role: Collaborator
Withdrawn
Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial
Research Design and Methods: The study will be a multicenter, randomized, controlled, clinical trial comparing the anti-seizure effect of parenteral and/or oral labetalol (n = 4000) versus parenteral (intravenous or …
Baylor Role: Lead Sponsor
Withdrawn
Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension
The purpose of the study is to find out if taking a dose of gabapentin 600 mg by mouth (po) before surgery will help prevent the development of tourniquet pain …
Baylor Role: Lead Sponsor
Unknown Status
Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is an orphan disease characterized by pulmonary artery hypertrophy, and resulting vascular remodeling of involved vessels, often leading to right heart failure. Accumulating evidence from vascular …
Baylor Role: Lead Sponsor
Completed
Improving Outcomes Using Collaborative Group Clinics to Empower Older Patients
Among persons aged 55-84 years, over 65% have one to three common medical conditions (e.g., hypertension, diabetes, arthritis, stroke, heart disease, etc.). Fortunately, large randomized clinical trials have demonstrated the …
Baylor Role: Lead Sponsor
Withdrawn
Pharmacogenomics in Pulmonary Arterial Hypertension
This study will make use of a large population of well defined patients with Pulmonary Arterial Hypertension who were enrolled in Encysive Pharmaceutical's STRIDE clinical trials or who have received …
Baylor Role: Collaborator
Completed
Physician Uncertainty Reduction for Hypertension
BACKGROUND: A large amount of literature suggests that the majority of "uncontrolled" hypertensives are under medical care, and that lack of control is largely explained by physicians not intensifying treatment …
Baylor Role: Lead Sponsor
Completed
Improving Hypertension Care for Inner City Minorities
BACKGROUND: The study was in response to a demonstration and education initiative, "Improving Hypertensive Care for Inner City Minorities", which was reviewed and approved by the Clinical Applications and Prevention …
Baylor Role: Lead Sponsor
Completed
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension
PROTOCOL OUTLINE: Patients are treated with a chronic continuous infusion of epoprostenol. The highest tolerated infusion rate is determined for each patient by gradually increasing the rate until the target …
Baylor Role: Collaborator